EGFR and cancer: Small molecule EGFR inhibitors, such as erlotinib, gefitinib and lapatinib, compete specifically with ATP for bind to the catalytic tyrosine kinase domain, inhibiting autophosphorylation processes and downstream signaling of cancer cells [18].